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1. Introduction 
Behçet disease is a multisystem disease of unknown cause in which an inflammatory 
perivasculitis can arise in almost any tissue (Sakane et al., 1999). Neurologic involvement in 
Behçet disease was first reported by Knapp in 1941. It represented between 4-49% of 
manifestations of BD (Haghighi et al., 2005). There is one of the most serious causes of long 
term morbidity and mortality in Behçet’s Disease. As well as, involvement of the central 
nervous system occurs late in the course of the disease (10–25%) (Ildan et al., 1996; Nakasu et 
al., 2001). It is caused by primary neural parenchymal lesions or is secondary to major 
vascular involvement (Adnan et al, 2009). 
Treatment of the most cases of NB should be given as infusion of intravenous methyl 
prednisolone followed by a slowly tapering course of oral steroids. (Adnan et al., 2000,). 
Immunopressives agents should be used in its severity forms of NB such as 
meningoencephalitis, deep veins thrombosis and myelopathy. In this Review, we 
summarise and describe the clinicals manifestations  of  neurobehcet disease.  
2. Epidemiology 
Epidemiological, Clinical characterization  and pattern of neurological involvement of 
Behcet’s disease have been reported in different series (Hentati et al., 1993; bohlega et al., 
1993; nakamura et al., 1994; Farah et  al,1998; Kidd et al.,1999; Akman et al.,1999; Al fahad et 
al.,1999). 
Retrospective and prospective studies found that the prevalence of Neurobehcet disease 
(NBD) is very variable. Neurologic involovement were occured in 2-49% of cases, other 
authors estimated their prevalence of 3-50% of cases (Borhani et al., 2009). The age of onset 
of NBD is usually 20–40 years with an average age of 39 years.  In two the last decade, 
Neurological complications  have also been described in children. (Adnan et al., 2005 ; Araji 
et al., 2009). 
The highest incidence is in the Middle East, the Mediterranean basin, and the Far East 
regions, but it is rare in Europe and North America. The frequency was 13% in men and 
5・6% in women. Neurological manifestations commonly develop a few years after the 
onset of the other systemic features of BD; The mean duration between onset of BD and 
development of NBD ranged from 3 to 6 years. (Siva et al., 2001). However, neurological 
syndrome might coincide or come in advance (~6% of patients) with other systemic 
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symptoms features of BD, in that case diagnosis can be difficult and causes ambiguity with 
other systemic diseases (Akman et al., 1999). 
3. Classification 
There are two categories of neurological involvement in BD that have been generally 
accepted: parenchymal involvement and non-parenchymal involvement, also called cerebral 
angio-Behcet’s syndrome. The most syndromes often involved in NBD were 
meningoencephalitis, myelopathy and deep veins thrombosis which presented 80% in 
retrospective series (Tohme et al., 2008) 
4. Neuropathology 
NBD is considered as an inflamatory perivasculitis disease, in an acute meningoencephalitis 
the most common neuropathologic findings are Severe and acute inflammation consisting 
mainly of lymphocytic, eosinophils, macrophages, and neutrophilic infiltrations of the 
perivascular spaces and parenchyma. These lesions can lead to necrotizing and 
disseminated encephalitis involving the basal ganglia, brainstem, cerebellum and 
diencephalon. 
In the progressive phase, authors found the inflammatory infiltration of lymphocytes and 
cytokines remains and cuts down. (Hirohata et al., 2008; Heo et al., 2008;  Hadfi et al., 1996; 
Arai et al., 2006;  Scardamaglia et al., 2001). 
5. Clinical characteristics 
In order to the accumulated data, it’s now obvious that it is necessary to handle 
parenchymal CNS involvement and non parenchymal CNS involvement in Behçet’sdisease 
separately. 
5.1 Parenchymal CNS involvement 
About 70 à 80% CNS involvement  
First of all, Subacute meningoencephalitis accounts for 75% of cases in parenchymal NBD, 
which performs adverse symptoms, depending on the topography of lesions. 
It’s and often associated with exacerbation of the systemic features of BD, including fever, 
malaise, orogenital ulcers, skin lesions, or uveitis (Akman et al., 2003; Joseph et al., 2007). 
The onset of signs is in the most cases acute or subacute. More rarely, the onset is chronic 
(Akman et al., 1999). Onset is usually with an attack of headache, hemiparesis and / or 
gradual behavioural changes. The symptoms and signs are taking a few days to attempt 
Summit and during several weeks, rely on depending on the extent of the lesion and on how 
rapidly treatment is initiated. However, spontaneous remissions of symptoms could be 
taken before initiation of therapy as it has been reported (Hirohata et al., 2007).  
Different syndromes might be encountered during the course of parenchymal NBD. 
The patient may frequently show brainstem signs, including pyramidal bilateral and 
cebellar syndromes, ophthalmoparesis and cranial neuropathy. Moreover, there is evidence 
for additional cerebral or spinal cord involvement like a day time sleeping with or without 
hyperphagia and which might be indicative of hypothalamic dysfunction (Wechsler et al., 
2002; Houmana et al., 2009) 
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Second a progressive form of the disease which represents 10% of cases of NBD, including, a 
worsening subcortical dementia, were usually accompanied by ataxia. 
Third, symptoms and signs suggestive of cerebral hemispheric involvement include 
encephalopathy, hemiparesis, Hemisensory loss, seizures, dysphasia, and mental changes 
with cognitive dysfunction and psychosis. 
Fourth, symptoms and signs of spinal cord involvement include pyramidal signs in the 
limbs, sensory level dysfunction, and, commonly, sphincter dysfunction.  
Finally, asymptomatic (silent) parenchymal NBD is diagnosed if there are no neurological 
symptoms, but neurological signs on examination (usually pyramidal signs ). Recognition of 
these clinical syndromes might help clinicians dealing with BD to predict the  pattern of 
involvement. They might also help neurologists to remember BD in the differential 
diagnosis of a patient who presents with one of these neurological syndromes. In addition, 
other clinical syndromes might arise in BD, and although uncommon, it is important that 
these syndromes are recognized. 
5.1.1 Epilepsy 
Neuro-BD-related epileptic disorder has been previously reported in a large series of Behçet 
disease. Generalized seizures are the predominant type (Aykutlu et al., 2002). Convulsions 
were observed in 2 - 5% of large series (Al-Fahad et al., 2001).Behcet’s syndrome may 
present with partial seizure and  epilepsia partialis continua (Aktekin et al., 2006.  Partial 
seizures were a presenting feature of NBD in one report (Chroni et al., 2008). 
5.1.2 Brain tumour 
Since the first described case in 1987; Focal necrotic lesions in the cerebral cortex; only a few 
cases have been published. (Litvan et al., 2005; Matsuo et al., 2005; Appenzeller et al., 2005; 
Kosters et al., 2006; Bennett et al., 2004; Park et al., 2002). 
The regions usually affected are, brainstem, diencephalon, basal ganglia, and internal 
capsule. The clinical presentation depends on the localizations of brain tumors; usually 
include intracranial hypertension syndrome and/or impaired of consciousness. These 
lesions cause a diagnosis problem with the brain tumor and a multiple metastatic tumors.  
5.1.3 Movement disorders 
Extrapyramidal manifestations whitch are indicating basal ganglion excessive dysfunction, 
are rare in most series of patients with NBD. 
5.1.4 Acute meningeal syndrome 
Aseptic meningitis commonly exists with many parenchymal CNS manifestations of BD. 
The signs and symptoms are relatively common in parenchymal NBD. However, isolated 
meningitis might only rarely be the presenting feature of NBD (Kidd et al., 1999; Akman et 
al., 1999; Al-Fahad et al., 1999). 
5.1.5 Optic neuropathy 
Optic neuropathy is rare in BD, it has been described only in0.4% of the main series of 
behçet disease. It can be bilateral and can be recurrent over many years. The severity of the 
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visual loss and its recovery can be very variable, even in the same patient (Voros et al., 2006; 
Tarzi et al., 2005). 
5.1.6 Spinal cord involvement 
Involvement of the spinal cord as part of the diffuse type of parenchymal NBD pattern is 
rare , represent 11% as reported by the most studies, thurly the spinal cord is commonly 
found to be involved in autopsy series of Behcet’s disease. More frequently a combination of 
spinal cord symptoms with other syndromes of parenchymal NBD, However isolated acute 
transverse myelitis is an exceptional presentation of NBD (Joseph, 2007). 
Most commonly patients presented with sensory-motor symptoms, sphincter and/or sexual 
dysfunction evolving over days. Although spinal cord involvement has a n worse prognosis 
compared with other types of p-NBD. The myelopathy can have a severe primary 
progressive course, a secondary progressive course after initial attack(s), or an acute attack 
with severe residual sequela after attacks (Houman et al., 2007; Moskau et al., 2003). 
14% had predominantly spinal cord involvement (10 with isolated spinal cord involvement 
and 13 with additional brainstem and/or hemispheric involvement. The cervical and/or 
dorsal areas can be involved (Kocer, 1999; Kizilkilic, 1998; Tunc et al., 2003; Calguneri et al., 
2005). 
5.2 Non-parenchymal NBD 
5.2.1 Cerebrovascular involvement 
Also called cerebral angio-Behcet’s syndrome, encompassing mainly those instances with 
dural sinus thrombosis. Cerebrovascular complications include strokes, carotid aneurysm 
formation and cerebral venous thrombosis (Hadfield et al, 1996; Tunc et al., 2004; B’chir-
Hamzaoui et al., 2009) 
5.2.1.1 Cerebral venous thrombosis   
In 1959, with headache and bilateral papilloedema. CVT constituted about 18% of  
NBD cases in the studies included, it’s reported to affect men more often than women  
and occurs at an earlier age.  Clinical onset is acute or subacute  in most patients.  
Chronic onset is less frequent. Patient has an intracranial hypertension. a focal deficits, 
seizures and /or counsiousness impairement (Yesilot et al., 2006; Bousser et al., 2007; 
Akman et al., 1999).  
The superior sagittal sinus is the most common site of thrombosis, followed by transverse 
sinuses, deep cerebral veins and cavernous sinuses, respectively (Mossadeq et al.,  
2004). 
Deep cerebral vein thrombosis is a specific clinical pattern of neuroBehçet. The clinical 
features of Rosenthal or internal cephalic vein thrombosis predominate. The clinical 
presentation is highly suggestive of diagnosis confirmed by Imaging ; it’s a mesencephalic 
diencephalitis syndroma combining hemiparesis, hémiataxie and / or movement disorders 
and ophthalmoplegia by damage of III (Mossadeq et al., 2004). 
5.2.1.2 Ischemic stroke and cerebral vasculitis 
are unusual manifestations during the course of BD, it was reported in1-5% of major series 
in the literature (1999; Al-Araji et al., 2003; Al-Fahad et al., 1999; Barros et al., 2007; 
Benamour et al., 2006; Borhani-Haghighi et al., 2006; Houman et al., 2007; Joseph et al., 2007; 
Monaco et al., 2006; Turker et al., 2008). 
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5.2.1.3 Aneurysm formation 
Aneurysm formation is common in the visceral arteries in BD, but extremely rare in the 
intracranial.vasculitis may be involved in the etiology of intracranial aneurysms in patients 
with BD (Kaku et al., 2007). 
5.2.2 Intracranial hypertension 
Hypertension manifests as an acute or, more commonly, subacute evolution of headache 
(92%), papilledema (80%), focal neurologic deficits (32%), seizures (20%), sixth-nerve palsy 
(16%) and/or altered consciousness (8%). Intracranial hypertension with or without cerebral 
vein thrombosis appears in 11–35% of all patients. Dural sinus thrombosis, more frequently 
the superior sagittal sinus; is the main cause of raised intracranial pressure.  
In the other side, intracranial without sinus thrombosis or MRI abnormalities  have been 
reported in NBD (Pamiret al., 1981; Akman et al., 1996). 
5.3 Others 
5.3.1 Psychiatric and cognitive disorders 
Psychiatric or cognitive symptoms might be the earliest presentation of NBD,   patient can 
have a dementia  as a sole presentation of the disease.  Patients have usually a special pattern 
of cognitive decline in with impaired memory, attention, and frontal lobe functions, and poor 
motivation and personality change, by contrast with relatively preserved linguistic, arithmetic, 
visuospatial, abstraction, and problem-solving abilities (Akman et al., 1999). 
Psychosomatic symptoms, such as anxiety and depression, are the most commonly 
encountered, in BD. These symptoms are mostly related to the underlying systemic disease, 
fatigue, functional deterioration, and sociological handicap, but are only rarely due to direct 
involvement of the CNS (Taner et al., 2007). Behavioural changes were common; where as 
major psychiatric symptoms were less common in large series (Akman et al., 1999; Al-Fahad 
et al., 1999; Siva, 2001).  
It is possible that psychiatric symptoms could be the first manifestation of the disease. To 
our knowledge, this is the first case report of Neuro-Behçet ’s Syndrome that presents with 
an acute psychotic attack (Orhan, 2009). 
Abnormal cognitive performances were present in 87.8% of the patients, with the most 
commonly and most severely affected function being long term memory for both verbal and 
visual modalities, followed by attention, and executive functioning, whereas only 9% of BD 
patients also showed cognitive deficits in visuospatial functions  
(Roberto, 2004) found that the main cognitive domain. Previous papers reporting cognitive 
dysfunction in BD patients in- cluded participants with neurological involvement (Akman et 
al., 1999; Oktem et al., 1999). 
However the recent studies reported that BD patients without overt neurological 
involvement are more likely to have cognitive impairment (Al-Arajiet al., 2009; Wechsler et 
al., 2002; Taner et al., 2007). 
5.3.2 Peripheral nervous system involvements 
Peripheral nervous system manifestations are relatively rare in BD. Isolated cases of peripheral 
neuropathy or myopathy have been reported in Behçet’s disease, they are essentially a case of 
multiple neuropathies, sensorimotor peripheral neuropathy, neuropathy autonomic 
dysfunction a Guillain Barré syndrome and hearing loss (Namer et al., 1987). Causes of 
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sensorineural hearing loss include central Causes of sensorineural hearing loss include central 
and peripheral nerve disorders. In particular, sensorineural hearing loss due to peripheral 
neuropathy was reported to be very rare (AK, 2004). Few series have described the clinical 
manifestations (Namer et al., 1987; Worthmann et al., 1996; Ben Ghorbel et al., 2005). 
Muscle involvement seems to be exceedingly rare in adults but more common in children. 
Patients present with a myositis, occasionally localised, that can be detected by 
electromyography. The rarity of these reports should encourage clinicians to investigate 
extensively for alternatives before accepting BD as the diagnosis. 
5.3.3 Headache 
The study has revealed a very high prevalence of headache in an unselected population of 
patients with Behçet’s syndrome. The majority of headaches is of neurovascular type and 
the prevalence of visual or sensory aura is higher than that seen in the general population of 
migraine sufferers (Kidd et al., 2006). Headache is the most common neurological symptom 
in patients with BD, and occurs in about 70% of patients. . The frequency of headache in BD 
was similar to the prevalence of headache 
Headache syndromes (e.g., migraine and tension-type headache) affect about 50% of 
patients with BD, and account for 70% of all causes of headaches in BD. The characteristics 
of these primary symptoms in BD did not differ when compared with a headache clinic 
population (Aykutlu et al., 2006). 
The features of this headache varied between migraine, migraine like, and tension type 
(Borhani-Haghighi et al., 2008; Aykutlu et al., 2006; Saip et al., 2005). 
The most widely accepted criteria for the diagnosis of BD are the International BD Study 









The diagnosis of neurological involvement in BD is done mainly by clinical means; the 
ancillary investigations noted below help to suggest alternatives, and especially infective 
complications of treatment, but there is no diagnostic test for NBD (Adnan et al., 2009). No 
validated criteria for the diagnosis of NBD exist. Blood count and biochemical screening is 
used to identify the nature and severity of the systemic disorder and to identify signs of a 
superimposed infective complication. (Yazici et al., 2007).  
6.1 Blood test 
Blood count and biochemical screening is used to identify the nature and severity of the 
systemic disorder and to identify signs of a superimposed infective complication (Yazici et 
al., 2007). Erythrocyte sedimentation rate has been found to be associated with disease 
activity.  
HLA type B51 has been reported to be present in 60–70% of Turkish and Japanese patients, 
although in only 10–20% of European patients (Borhani et al., 2009). Patients with HLAB51 
have a six-time increased risk of BD, and the disease is usually more severe in such patients 
(Yazici et al., 2007). 
In the case of cerebral venous thrombosis (CVT), a thrombophilia screen should be 
undertaken. Early reports suggested a higher prevalence of antiphospholipid antibodies and 
factor V Leiden mutations, but these findings have not been confirmed (Adnan et al., 2009). 
6.2 Cerebrospinal fluid (CSF) 
CSF constituents are altered in around 70–80% of patients with parenchymal complications. 
CSF protein is modestly raised in most cases, sometimes to over 1 g/dL, and oligoclonal 
bands are usually absent (Akman et al., 1999). The CSF cell count is often prominently 
raised. (Borhani et al., 2008; Houman et al., 2007).  
In Hamzaoui et al. study, elevated CSF levels of IL-15 were seen in patients with NBD  
in comparison with the patients with non-inflammatory neurological disease (Hamzaoui  
et al., 2006).  
CSF levels of some major pro-inflammatory (IL-6, 8, TNF-_and interferon) and anti-
inflammatory (IL-10) cytokines in patients with different subtypes of NBD, In Niino et al. 
study, the concentration of macrophage migration inhibitory factor in CSF was significantly 
elevated in patients with NBD compared with control group and correlated well with CSF 
cell count (Niino et al. , 2000).  
Significance of elevation of interleukin 6 in patients with parenchymal NBD was found (A. 
Borhani et a.l, 2009). 
The level of interleukin-6 dropped when the disease activity subsided.  
These changes were in parallel with IgM isotype of anticardiolipin antibodies (Wong et al., 
1992).In Hirohata et al. study 11 patients with progressive NBD showed significant elevation 
of CSF interleukin-6 activities in comparison with patients with active BD without 
progressive neurological manifestations.  
Serum interleukin-6 activities of these groups did not revealed significant difference 
(Hirohata et al., 1997).  
CSF interleukin-6 levels were used as a parameter for investigation of response of six 
patients with NBD to low dose methotrexate.  
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After 12 months trial CSF interleukin-6 levels were significantly decreased. However six 
months after discontinuation of methotrexate, all patients showed significant exacerbation 
evidenced by a decrease in verbal intelligence quotients along with the marked elevation of 
CSF interleukin 6( Hirohata et al., 1998). 
6.3 MRI 
However, there were still limitations in differential diagnosis with tumor, abscess, multiple 
sclerosis, and other vasculitis (Joseph et al., 2007; Miller et al., 1987.; Litvan et al., 1987; Mnif 
et al., 2006; Neudorfer et al., 1993; Imoto et al., 2002; Tuzgen et al., 2002; Bennet et al., 2004;  
A. Tourba et al., 2011).  
In Neurobehçet’s disease, the most common site was brainstem and the next most common 
sites were basal ganglia and white matter.  
Cerebellar lesion was reported in a few cases (Kocer et al., 1999; Jae-Hyeok et al., 2008).  
Patients with a more diffuse meningoencephalitis show hyper intense T2 lesions within the 
subcortical white matter of the temporal, frontal, and hypothalamic regions, but the scan 
might also be normal.  
Patients with spinal cord involvement show a single lesion, which might look like a 
demyelinating plaque, but might extend over two or three segments.  
Venous sinus thrombosis is readily seen on magnetic resonance venography and brain CT 
venography. Patients who present with idiopathic intracranial hypertension have normal 
imaging studies (Ak man et al., 2003; Coban et al., 1999; Siva et al., 2009). 
7. Treatment 
The severe nature of the neurological involvement in BD obligates the innovation of 
markers of disease activity or prognosis that can be determined early in the disease 
course (Guls et al., 2008). There have no controlled or comparative trials of treatment of 
any aspect of neurological involvement in BD. Based on scattered evidence, 
corticosteroids and immunosuppressive have proved effective in improving clinical 
symptoms of NBD. Remission can be defined as complete or nearly complete absence of 
symptoms. 
Corticosteroids should be given as infusions of intravenous methylprednisolone: 1g IV daily 
for 3 to 5 days followed by prednisone 0.5 to 1 mg/kg/d for acute attacks. Therefore 
prevention treatment for early relapses consists of prednisone which must be very gradually 
tapered over 2 to 3 months (Siva et al., 2000), followed by a slowly tapering course of oral 
steroids (Adnan et al., 2009). 
However , there is controversy about the choice of immunosuppressant therapy as  
an adjuvant to corticosteroids; immunosuppressive agents or tumor necrosis antagonists 
should be used at the same time or later depends on the nature of the disease, its severity, 
the response to steroids, and whether the patient has had previous attacks. In the 
retrospectives series, immunosuppressive therapy not be used until the second  
attack occurs, or if the disease is aggressive. Similarly, no treatment trial has been 
undertaken CVT.  
For dural sinus thrombosis associated with Behçet disease, concurrent use of corticosteroids 
and anticoagulants is suggested (Bank et al., 1984). Either intravenous unfractionated 
heparin or subcutaneous low-molecular-weight heparin can be used (Siva et al., 2001). 
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Some neurologists do not use anticoagulants at all, choosing instead to give steroids and 
immunosuppressants alone.  
Other neurologists prefer to use anticoagulants, but recent data show that 
immunosuppressants are underused (Adnan et al., 2009).  
In the literature, several immunosuppressive agents were previously reported, such as 
Azathioprine, Cyclophosphamide, Chlorambucil, thalidomide and Methotrexate. In most 
series, the most used immusupressant were Azathioprine and methotrexate. 
Cyclophosphamide (CPM) is only reported in only sporadic cases, and used in second 
intention (Homan et al., 2008; Hatemi et al., 2008; Kotter et al., 2005). 
More recently, some immunomodulators such as interferon, infliximab and thalidomide 
have been used successfully in treating some cases of Neurobehçet, but their effectiveness 
has been proven with any controlled study (Siva et al., 2009). 
In the study by O’Duffy et al., Chlorambucil with or without corticosteroids was more 
effective than corticosteroids alone for meningoencephalitis or recurrent meningitis 
(O’Duffy et al., 1984). In the Hirohata et al study, low-dose methotrexate reduced the CSF 
interleukin-6 level and seemed to ameliorate the course of neuropsychiatric manifestations 
(Hirohata, 1998).  
For patients with parenchymal Neurobehçet’s disease without any poor prognostic factor, 
Azathioprine or methotrexate and corticosteroids are recommended as the first line 
treatment. For high risk patients, intravenous Cyclophosphamide and corticosteroids are 
recommended (Borhani et al., 2009). 
8. Prognosis 
Neurobehçet’s disease has a high mortality rate, up to 25% within the first year after 
developing neurological manifestations (Wolf et al., 1965).  
Most patients who have an acute parenchymal inflammatory episode recover well after 
steroid treatment. Retrospective series from 10–15 years ago reported a mean of 20–30% of 
patients with residual neurological impairments, and a high 10-year mortality of 
10%.However, non-parenchymal CNS involvement is prominently associated with a better 
prognosis than parenchymal CNS involvement (Wechsler et al., 1992; Akman-Demir et al., 
1996; Siva et al., 1997). It should be noted that certain factors influence the course and 
prognosis of Neurobehçet cases. I a previous reported the most important of these is the 
correlation between the acute-stage CSF findings and the clinical cours (Akman-Demir et al., 
1996) normal CSF at the acute stage is associated with a better prognosis, stable course and 
less disability, while high cellular and/or protein content is significantly associated with a 
worse prognosis (Gu¨lsen Akman-Demir et al., 1999) 
9. Conclusion 
Neurological involvements are actually classified in two categories; a parenchymal and 
none parenchymal diseases. Their manifestations come many years after the outset of BD. 
The diagnosis is based according to the international criteria of a group study of Behçet 
disease. 
Moreover, clinical manifestations are critical and should be diagnosed earlier. The most 
serious involvements are parenchymal and vascular diseases because they engage vital and 
functional prognosis.   
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Therefore intensive therapy based on corticosteroids anticoagulation therapy and 
immunosuppressive only guarantees of improving their prognosis. 
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